On Tuesday, Shares of Vale S.A. (NYSE:VALE), lost -0.46% to $6.54. Yesterday, 43,985,260 shares have changed hands as compared to average volume of 34,438,700 share. The company holds market capitalization of 33.70B.
Global iron ore demand will contract over the 2020s as steel consumption growth in China peaks, according to Citigroup Inc., which reduced its long-run price forecast for the raw material by 32 percent, according to Bloomberg.
The long-run estimate was cut to $55 a metric ton from $81 as the world’s major mining companies added more cheap supply, analysts counting Ivan Szpakowski wrote in a report on Wednesday. From 2016 to 2018, prices may average $40, it said. Bloomberg Reports.
Vale S.A., together with its auxiliaries, engages in the research, production, and sale of iron ore and pellets, nickel, fertilizer, copper, coal, manganese, ferroalloys, cobalt, platinum group metals, and precious metals in Brazil and internationally.
Shares of American Airlines Group Inc. (NASDAQ:AAL), declined -2.48% to $41.56, during its last trading session.
The U.S. airline industry slipped into a bear market as investors worry that carriers are losing power to raise fares even as oil prices rise, according to Bloomberg.
The Bloomberg U.S. Airlines Index tumbled for a fifth straight day Tuesday, dropping 21 percent from its 2015 high on Jan. 26, a common definition of a bear market. The decline has occurred despite forecasts for a record industry profit this year and as planes fly with more than 80 percent of seats filled. Bloomberg Reports.
American Airlines Group Inc., through its auxiliaries, operates in the airline industry. As of December 31, 2014, the company operated 983 mainline jets, in addition to 566 regional aircrafts through regional airline auxiliaries and third-party regional carriers. It serves 339 destinations in 54 countries.
At the end of Tuesday’s trade, Shares of Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM), gained 29.41% to $3.74.
Actinium Pharmaceuticals, hosted a Key Opinion Leader (KOL) Breakfast for healthcare investors and industry professionals at the NY Palace Hotel.
The panelists discusssed the dire need for new therapies for older patients with hematologic malignancies counting acute myeloid leukemia (AML), and the curative role of bone marrow transplant. Iomab-B was described as having efficacy and safety superior to that of traditional myeloablative regimens, and likely to markedly enhance the number of patients eligible for transplant. An update on the forthcoming Phase 3 clinical trial of Iomab-B, plus clinical positioning and positive commercial prospects were also offered, and can be viewed online.
The meeting featured bone marrow transplant and hematology specialist Hillard M. Lazarus, MD, a Professor of Medicine at Case Western Reserve University (CWRU) School of Medicine, in addition to Disease Team Leader and Director of Novel Cell Therapy at University Hospitals, Case Medical Center, and Company Scientific Advisory Board Member. Also featured was radiopharmaceutical industry veteran Roland U. Turck, MD, Managing Partner at TurckBio and recently-designated Senior Advisor to the Actinium Board of Directors. Dr. Turck has extensive, unparalleled experience in the launch and commercialization of radiopharmaceuticals.
Dr. Lazarus performed the first bone marrow transplant in Ohio in 1976, and has had a seminal impact on multiple aspects of transplantation He now heads several clinical trials at the National Center for Regenerative Medicine (CWRU). He has over 500 publications and has won a variety of lifetime achievement, distinguished alumnus, and cancer research awards, in addition to fellowships sponsored by the Leukemia Society of America and the American Cancer Society.
Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy platform and other related and similar technologies.
Finally, ICICI Bank Ltd. (NYSE:IBN), ended its last trade with -1.34% loss, and closed at $10.32. The company attained the volume of 7,043,068 shares as compared to its average volume of 8,165,740 shares. It opened the trade with $10.36, and after floating between $10.26 - $10.50, settled at $10.32.
Financial stocks were declining Tuesday with the NYSE Financial Sector Index dropping 1.2% and the S&P Financial 100 Index falling 0.9%.
ICICI Bank Limited, together with its auxiliaries, provides banking and financial services to the corporate and retail customers. It offers commercial banking, retail banking, project and corporate finance, working capital finance, insurance, venture capital and private equity, investment banking, broking, and treasury products and services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
